MA44126A - Méthodes de traitement de maladies et troubles pulmonaires - Google Patents
Méthodes de traitement de maladies et troubles pulmonairesInfo
- Publication number
- MA44126A MA44126A MA044126A MA44126A MA44126A MA 44126 A MA44126 A MA 44126A MA 044126 A MA044126 A MA 044126A MA 44126 A MA44126 A MA 44126A MA 44126 A MA44126 A MA 44126A
- Authority
- MA
- Morocco
- Prior art keywords
- disorders
- treatment
- methods
- lung diseases
- lung
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562271191P | 2015-12-22 | 2015-12-22 | |
US201562271804P | 2015-12-28 | 2015-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA44126A true MA44126A (fr) | 2018-10-31 |
Family
ID=57758846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA044126A MA44126A (fr) | 2015-12-22 | 2016-12-22 | Méthodes de traitement de maladies et troubles pulmonaires |
Country Status (6)
Country | Link |
---|---|
US (3) | US20180369209A1 (fr) |
EP (1) | EP3393465A1 (fr) |
AU (1) | AU2016379388A1 (fr) |
CA (1) | CA3009339A1 (fr) |
MA (1) | MA44126A (fr) |
WO (1) | WO2017112853A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3157917B1 (fr) * | 2014-06-19 | 2020-03-18 | Proteostasis Therapeutics, Inc. | Composés, compositions et procédés pour augmenter l'activité du cftr |
WO2016105468A1 (fr) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Dérivés de 3-hétéroarylisoxazol-5-amide carboxylique utiles dans le traitement, entre autres, d'une fibrose kystique |
WO2016105477A1 (fr) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc | Dérivés d'amides 5-phényl- ou 5-hétéroarylthiazol-2-carboxyliques servant au traitement, entre autres, de la fibrose cystique |
WO2016105484A1 (fr) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Dérivés d'amide 5-(hétéro)arylpyrazol-3-carboxylique ou d'amide 1-(hétéro)aryltriazol-4-carboxylique utiles pour le traitement, entre autres, de la fibrose kystique |
MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
AU2016297886B2 (en) | 2015-07-24 | 2020-12-10 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing CFTR activity |
CA3000483C (fr) | 2015-10-06 | 2024-02-13 | Proteostasis Therapeutics, Inc. | Composes, compositions et methodes permettant de moduler le cftr |
EP3440057B1 (fr) | 2016-04-07 | 2021-09-22 | Proteostasis Therapeutics, Inc. | Analogues du ivacaftor conentant des atomes de silicium |
MA45397A (fr) | 2016-06-21 | 2019-04-24 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
EP3814336A1 (fr) | 2018-06-27 | 2021-05-05 | Proteostasis Therapeutics, Inc. | Composés améliorant l'activité du protéasome |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007075896A2 (fr) * | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Inhibiteurs de cytokine heterocycliques |
US20090069288A1 (en) * | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
WO2010089297A1 (fr) * | 2009-02-04 | 2010-08-12 | N.V. Organon | Dérivés d'isoxazole-5-carboxamide |
WO2014181287A1 (fr) * | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Composés hétérocyclyliques et leurs utilisations |
WO2015138934A1 (fr) * | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Composés, compositions et procédés pour augmenter l'activité cftr |
US9855249B2 (en) * | 2014-10-02 | 2018-01-02 | Flatley Discovery Lab, Llc | Isoxazole compounds and methods for the treatment of cystic fibrosis |
MA41253A (fr) * | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
AU2016297886B2 (en) * | 2015-07-24 | 2020-12-10 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing CFTR activity |
CA3000483C (fr) * | 2015-10-06 | 2024-02-13 | Proteostasis Therapeutics, Inc. | Composes, compositions et methodes permettant de moduler le cftr |
UA125400C2 (uk) * | 2016-11-18 | 2022-03-02 | Цистік Фіброзис Фаундейшн | Піролопіримідин як потенціатор трансмембранної провідності при муковісцидозі (cftr) |
-
2016
- 2016-12-22 EP EP16823527.3A patent/EP3393465A1/fr not_active Withdrawn
- 2016-12-22 CA CA3009339A patent/CA3009339A1/fr active Pending
- 2016-12-22 AU AU2016379388A patent/AU2016379388A1/en not_active Abandoned
- 2016-12-22 WO PCT/US2016/068266 patent/WO2017112853A1/fr active Application Filing
- 2016-12-22 MA MA044126A patent/MA44126A/fr unknown
- 2016-12-22 US US16/065,384 patent/US20180369209A1/en not_active Abandoned
-
2021
- 2021-06-22 US US17/354,751 patent/US20220175735A1/en active Pending
-
2023
- 2023-12-15 US US18/542,018 patent/US20240139158A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3393465A1 (fr) | 2018-10-31 |
AU2016379388A1 (en) | 2018-07-12 |
US20240139158A1 (en) | 2024-05-02 |
US20180369209A1 (en) | 2018-12-27 |
WO2017112853A1 (fr) | 2017-06-29 |
US20220175735A1 (en) | 2022-06-09 |
CA3009339A1 (fr) | 2017-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44126A (fr) | Méthodes de traitement de maladies et troubles pulmonaires | |
MA46365A (fr) | Méthodes de traitement de troubles mitochondriaux et métaboliques | |
HK1246712A1 (zh) | 神經刺激治療疾病及病症 | |
IL262608A (en) | Combined treatment of eye disorders and inflammatory diseases | |
HK1246179A1 (zh) | 治療視網膜疾病的方法 | |
EP3119913A4 (fr) | Procédés et compositions pour le traitement de maladies immunitaires ou de troubles et/ou la surveillance thérapeutique | |
IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
MA48996A (fr) | Méthodes de traitement de maladies neurodégénératives | |
ZA201702214B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
EP3104776A4 (fr) | Diagnostic et traitement de troubles respiratoires | |
EP3273955A4 (fr) | Traitement de maladies respiratoires | |
LT3157531T (lt) | Žarnyno enteroendokrininės sistemos stimuliavimo būdai ir kompozicijos, skirtos su ja susijusioms ligoms arba būklėms gydyti | |
MA42930A (fr) | Traitement de maladies neurodégénératives | |
MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
MA41462A (fr) | Méthode de traitement de maladies | |
IL264070A (en) | Methods and preparations for the treatment of disorders and diseases involving rdh12 | |
HK1258994A1 (zh) | 用於疾病治療的方法 | |
MA39950A (fr) | Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie | |
EP3341012A4 (fr) | Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles | |
IL242694B (en) | A subpopulation of monocytes of human origin for the treatment of eye diseases | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
HK1219654A1 (zh) | 用於治療眼科疾病和病症的方法 | |
HK1245671A1 (zh) | 使用白細胞介素-10治療疾病和病症的方法 | |
IL260987A (en) | Treatment and diagnosis of inflammatory disorders | |
GB201805100D0 (en) | Treatment of sarcopenic diseases |